Remove Allergies Remove Clinical Research Remove Immune Response
article thumbnail

Kaiser Permanente Joins Late-Stage Trial for Pfizer and BioNTech’s Lead COVID-19 Vaccine Candidate

XTalks

It is also dedicated to fostering innovations in care, clinical research, health education and the support of community health. Kaiser Permanente is also involved in the testing of Moderna’s investigational COVID-19 vaccine, which is being co-developed by the National Institute of Allergy and Infectious Diseases (NIAID).

article thumbnail

HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins

XTalks

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Action Alert: Merck, Aurinia and Amgen

The Pharma Data

It was co-sponsored by Merck and Bayer, conducted with the scientific oversight of the Canadian VIGOUR Centre and the Duke Clinical Research Institute. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. Aurinia Pharmaceutical’s Voclosporin for Lupus Nephritis.

article thumbnail

Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline.

Delveinsight

The company is making the vaccine alongside the Bill & Melinda Gates Foundation that proffered a grant to fund preclinical work, and the National Institute of Allergy and Infectious Diseases, which will perform a phase 1 study via the Infectious Diseases Clinical Research Consortium.

article thumbnail

Preventing the next pandemic: Supporting early-stage R&D

pharmaphorum

Once the pandemic hit, Moderna teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID) to co-develop the former’s vaccine. The institute also led and funded early-stage clinical research into the vaccine candidate. Identifying the threat.

article thumbnail

NIH begins clinical trial evaluating second COVID-19 booster shots in adults

The Pharma Data

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Fauci, M.D. Investigators aim to have initial findings available by August 2022.

article thumbnail

COVID-19 Pandemic Coverage

XTalks

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. China’s COVID-19 Vaccine: Sinovac Biotech and CanSino Biologics.